Roche Delays CERA Oncology Filing Until 2009
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche is pushing back the timeline for filing its anti-anemia agent CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the firm said Feb. 1